Surrozen, Inc. (SRZN)
Market Open
3 Apr, 17:01
NASDAQ (CM) NASDAQ (CM) Primary $
11. 68
-0.18
-1.52%
$
29.59M Market Cap
- P/E Ratio
0% Div Yield
25 Volume
-11.7 Eps
$ 11.86
Previous Close Day Range
11.68 11.68
Year Range
6 18.17
Summary
SRZN trading today higher at $11.68, an increase of -1.52% from yesterday's close, completing a monthly increase of 0.09% or $0.01. Over the past 12 months, SRZN stock lost -17.99%.
SRZN is not paying dividends to its shareholders.
The last earnings report, released on Apr 01, 2025, missed the consensus estimates by -8.6%. On average, the company has fell short of earnings expectations by -1.67%, based on the last three reports.
Surrozen, Inc. has completed 1 stock splits, with the recent split occurring on Dec 14, 2023.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (CM) (USD).
Want to track SRZN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
SRZN Chart
Surrozen, Inc. Dividends
SRZN is not paying dividends to its shareholders.
Surrozen, Inc. Earnings
| 1 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2024 Date | | - Cons. EPS | - EPS |
| 8 May 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2024 Date | | - Cons. EPS | - EPS |
SRZN is not paying dividends to its shareholders.
| 1 Apr 2025 Date | | - Cons. EPS | - EPS |
| 6 Nov 2024 Date | | - Cons. EPS | - EPS |
| 7 Aug 2024 Date | | - Cons. EPS | - EPS |
| 8 May 2024 Date | | - Cons. EPS | - EPS |
| 7 May 2024 Date | | - Cons. EPS | - EPS |
Surrozen, Inc. (SRZN) FAQ
What is the stock price today?
The current price is $11.68.
On which exchange is it traded?
Surrozen, Inc. is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is SRZN.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 29.59M.
Has Surrozen, Inc. ever had a stock split?
Surrozen, Inc. had 1 splits and the recent split was on Dec 14, 2023.
Surrozen, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Craig C. Parker M.B.A. CEO | NASDAQ (CM) Exchange | US86889P1093 ISIN |
| US Country | 42 Employees | - Last Dividend | 14 Dec 2023 Last Split | 11 Jan 2021 IPO Date |
Overview
Surrozen, Inc. is a pioneering force in the field of biotechnology, focusing on the clinical stage development of innovative drug candidates. With a mission firmly centered around tissue repair and regeneration, Surrozen is at the frontier of manipulating the Wnt signaling pathway—a crucial axis in cellular growth and differentiation. This biotech entity is passionately engaged in crafting antibody-based therapeutics designed to have a transformative impact across a multitude of disease spheres. Since its inception in 2015, Surrozen has made its home in South San Francisco, California, positioning itself in the heart of a vibrant life sciences hub. The company's strategic partnership with Boehringer Ingelheim International GmbH underscores its commitment to advancing the frontiers of medicine through collaborative innovation and the pursuit of groundbreaking R&D initiatives.
Products and Services
- SZN-043: This hepatocyte-specific R-spondin mimetic bispecific fusion protein represents a cornerstone of Surrozen’s pipeline. Currently navigating through a Phase 1b clinical trial, SZN-043 targets severe liver diseases, such as alcoholic hepatitis, showcasing the company’s dedication to addressing critical needs in hepatology. By engaging with the asialoglycoprotein receptor 1, this therapeutic endeavor embodies Surrozen’s innovative approach to liver health and disease management.
- SZN-1326: As a testament to Surrozen’s dedication to combating gastrointestinal disorders, SZN-1326 emerges as a bi-specific antibody currently under the scrutiny of a Phase 1b clinical trial. This promising candidate is engineered to tackle moderate to severe inflammatory bowel disease by targeting the Frizzled and LRP receptors, pivotal components in the modulation of the Wnt signaling pathway and thus inflammation and tissue repair processes.
- SZN-413: Venturing into the realm of ophthalmology, SZN-413 is a Fzd4 targeted bi-specific antibody, presently in the preclinical developmental stage. This innovative therapeutic seeks to mitigate the impact of retinal vascular associated diseases, illuminating Surrozen’s commitment to addressing a wide spectrum of unmet medical needs through the intricate manipulation of the Wnt signaling axis.
Contact Information
Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 489 9000
Website: https://www.surrozen.com
2025 © Marketlog. All Rights Reserved.
